# Signals Article: Investigating the Putative Target P26439 for Polycystic Ovary Syndrome
Background
Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder affecting women's health, characterized by hormonal imbalance, irregular menstrual cycles, and polycystic ovaries. Despite its prevalence, the underlying biological mechanisms remain incompletely understood, necessitating the identification of novel therapeutic targets. One such putative target is the protein encoded by UniProt accession P26439. Preliminary expression data suggest that P26439 may play a role in the pathophysiology of PCOS, but its therapeutic potential has yet to be fully explored.
Data-mining rationale
The identification of P26439 as a candidate target for PCOS emerged from a comprehensive data-mining effort. This involved cross-referencing UniProt's reviewed human entries associated with PCOS against 49 microarray datasets available in the NCBI Gene Expression Omnibus (GEO). The expression-profiling studies indicated the presence of P26439 in relevant datasets, suggesting its potential involvement in the mechanisms underlying PCOS. Notably, there are currently no registered Phase 1 or higher clinical programs targeting this candidate, highlighting a significant gap in its potential clinical application.
Why prior analyses may have missed this
Many of the GEO datasets utilized in this analysis were generated before the adoption of modern empirical-Bayes statistical methods, such as the limma package, which are crucial for accurate differential expression analysis. The absence of rigorous multiple-testing corrections in earlier studies may have led to the underreporting of significant findings, including the role of P26439 in PCOS. Re-analysis of these datasets using contemporary statistical approaches could yield new insights into the expression patterns and relevance of this putative target.
Reasoning for further validation
To substantiate the potential role of P26439 in PCOS, several experimental steps are suggested:
1. **Re-analyze the matched GEO datasets** using the limma package with a Benjamini-Hochberg false discovery rate (FDR) threshold of less than 0.05 to accurately identify differentially expressed genes associated with PCOS.
2. **Validate the top differentially expressed genes** by quantitative PCR (qPCR) in an independent cohort to confirm the expression patterns observed in the initial analysis.
3. **Check tissue specificity** of P26439 expression using resources like the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas to determine its relevance in tissues related to PCOS.
4. **Run pathway analyses** using tools such as STRING or OmniPath to contextualize P26439 within relevant biological pathways that may be implicated in PCOS.
5. **If validated**, assess the druggability of P26439 through databases such as DGIdb and ChEMBL to explore potential therapeutic avenues.
These steps will provide a clearer understanding of the role of P26439 in PCOS and its potential as a therapeutic target.